Table 3.

Mean bone marker values^a (95% confidence intervals) at baseline, 1 month and 6 months in the treatment naïve, AR pretreated and inadequate AR responder subgroups

	Treatment naive	AR pretreated	Inadequate AR responder	p-valueb
				AR pretreated vs. naive	Inadequate AR responder vs. naive	AR pretreated vs. inadequate AR responder
PINP (μg/L)
Baseline	48.2 (43.8 – 53.1)	26.1(23.8 – 28.5)	27.5 (25.7 – 29.4)	<0.0001	<0.0001	0.363
1 month	85.5 (78.0 – 93.6)	56.6 (52.0 – 61.6)	62.2 (58.4 – 66.3)	<0.0001	<0.0001	0.079
6 months	129.1 (116.1 – 143.5)	118.2 (106.9 – 130.6)	136.6 (126.8 – 147.2)	0.235	0.387	0.022
b-ALP (μg/L)
Baseline	12.9 (12.1 – 13.7)	10.1 (9.6 – 10.7)	10.2 (9.8 – 10.7)	<0.0001	<0.0001	0.775
1 month	14.3 (13.5 – 15.2)	12.0 (11.4 – 12.7)	12.4 (11.9 – 12.9)	<0.0001	<0.0001	0.374
6 months	18.9 (17.6 – 20.3)	17.6 (16.5 – 18.8)	19.2 (18.3 – 20.2)	0.152	0.749	0.045
t-ALP (μg/L)
Baseline	69.6 (66.5 – 72.9)	64.1 (61.4 – 66.9)	63.3 (61.3 – 65.4)	0.010	0.001	0.655
1 month	72.5 (69.4 – 75.7)	67.9 (65.2 – 70.8)	68.0 (65.9 – 70.1)	0.034	0.019	0.976
6 months	82.9 (79.0 – 87.0)	82.1 (78.5 – 85.9)	84.1 (81.3 – 87.0)	0.777	0.630	0.407

^aAdjusted by baseline P1NP concentration and BMD values, and duration of prior AR treatment

^bMMRM of log-transformed data

AR = antiresorptive; PINP = procollagen Type 1 N-terminal propeptide; b-ALP = bone-specific alkaline phosphatase; t-ALP = total alkaline phosphatase